Archive for the ‘Adnexus Therapeutics’ Category

Bristol CEO touts successful biopharma blitz after big hep C play

January 11th, 2012 Ryan McBride

Bristol-Myers Squibb ($BMY) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed “String of Pearls” strategy advanced to buy biotechs that brought BMS new drugs and science. Bristol-My…

Posted in Adnexus Therapeutics, Blog, Bristol-Myers Squibb, Companies, Diagnostics, Funding, Hepatitis C, Inhibitex, Medarex, Medical Devices, Medical Supply, Mergers and Acquisitions, Pfizer, Pharmaceuticals, Startups, Universities, Videos, Yervoy Tags: Comments Off
Read More »